Tratamento da síndrome da apneia obstrutiva do sono: revisão da literatura [PDF]
, 2022 The objective of this review was to identify the main treatments available for obstructive sleep apnea syndrome. A search for information was carried out in Pubmed, BVS, Science Direct, Scopus, Web of Science, Scielo, Ovid, Lilacs, Research Gate, and ...
Idrovo Rojas, Trudy +3 more
core +3 more sources
0751 Epworth Sleepiness Scale Test-Retest Reliability Analysis In Solriamfetol Studies [PDF]
Sleep, 2020 Abstract Introduction The Epworth Sleepiness Scale (ESS) measures excessive daytime sleepiness. This analysis examined test-retest reliability of ESS scores in participants with narcolepsy or obstructive sleep apnea (OSA) in solriamfetol studies ...
J Black +6 more
openaire +1 more source
Use of empagliflozin as an adjuvant treatment for obstructive sleep apnea for a patient who has not seen a physician in over 40 years [PDF]
A clinical decision report using: Neeland IJ, Eliasson B, Kasai T, et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2020;43(12):3007-
Demko, Andrew
core +2 more sources
Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA. [PDF]
Sleep Med, 2023 BACKGROUND Obstructive sleep apnea (OSA) is a chronic condition characterized by intermittent hypoxia (IH). Excessive daytime sleepiness (EDS) is a common consequence of OSA and is associated with cognitive deficits and anxiety.
Badran M +4 more
europepmc +2 more sources
Work productivity and activity impairment in patients with narcolepsy type 1 [PDF]
, 2023 The aim of this study was to assess work productivity and activity impairments and to explore their association with excessive daytime sleepiness, body mass index (BMI), depression, and anxiety in patients with narcolepsy type 1.
Bassi, Chiara +7 more
core +2 more sources
0756 Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion
Sleep, 2022 Abstract Introduction Solriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The wake-promoting mechanism of solriamfetol may result from dopamine and norepinephrine reuptake inhibition ...
Hema Gursahani +5 more
openaire +1 more source
Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments [PDF]
, 2023 Research into the involvement of adrenoceptor subtypes in the cause(s) of psychiatric disorders is particularly challenging. This is partly because of difficulties in developing animal models that recapitulate the human condition but also because no ...
Heal, David J, Stanford, S Clare
core
SLC6 neurotransmitter transporter family in GtoPdb v.2023.1 [PDF]
, 2023 Members of the solute carrier family 6 (SLC6) of sodium- and (sometimes chloride-) dependent neurotransmitter transporters [32, 2, 23, 75] are primarily plasma membrane located and may be divided into four subfamilies that transport monoamines, GABA ...
Bröer, Stefan, Rudnick, Gary
core +2 more sources
Secondary Narcolepsy as Worsening Sign in a Pediatric Case of Optic Pathway Glioma [PDF]
, 2022 Narcolepsy, a neurologic disorder that leads to excessive daytime sleepiness, may represent a rare consequence of neoplastic lesions involving the sellar/parasellar and hypothalamic regions, the anatomical areas responsible for wakefulness. Optic pathway
Cacchione, Antonella +8 more
core +3 more sources
Recent advances in treatment for narcolepsy
Therapeutic Advances in Neurological Disorders, 2019 Narcolepsy type 1 (NT1) is a chronic orphan disorder, caused by the selective and irreversible loss of hypocretin/orexin (ORX) neurons, by a probable autoimmune process.
Lucie Barateau, Yves Dauvilliers
doaj +1 more source